Lantheus Holdings, Inc. (NASDAQ:LNTH) Insider Sells $1,028,037.78 in Stock

Lantheus Holdings, Inc. (NASDAQ:LNTH) insider Daniel Niedzwiecki sold 12,873 shares of Lantheus stock in a transaction dated Thursday, May 30th. The stock was sold at an average price of $79.86, for a total value of $1,028,037.78. Following the sale, the insider now directly owns 80,244 shares of the company’s stock, valued at approximately $6,408,285.84. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Lantheus Stock Up 1.2 %

Lantheus stock opened at $82.52 on Thursday. The stock has a market capitalization of $5.72 billion, a PE ratio of 12.60 and a beta of 0.56. Lantheus Holdings, Inc. has a 12 month low of $50.20 and a 12 month high of $94.47. The business has a 50 day simple moving average of $70.31 and a 200-day simple moving average of $64.77. The company has a debt-to-equity ratio of 0.59, a current ratio of 4.84 and a quick ratio of 4.55.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings results on Thursday, May 2nd. The medical equipment provider reported $1.51 EPS for the quarter, topping the consensus estimate of $1.40 by $0.11. Lantheus had a return on equity of 54.10% and a net margin of 33.72%. The firm had revenue of $369.98 million during the quarter, compared to analysts’ expectations of $349.46 million. On average, analysts anticipate that Lantheus Holdings, Inc. will post 6.51 EPS for the current fiscal year.

Hedge Funds Weigh In On Lantheus

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its stake in Lantheus by 5.6% during the first quarter. Vanguard Group Inc. now owns 7,362,969 shares of the medical equipment provider’s stock worth $458,271,000 after buying an additional 389,828 shares during the last quarter. FMR LLC boosted its stake in Lantheus by 198.2% during the third quarter. FMR LLC now owns 2,146,085 shares of the medical equipment provider’s stock worth $149,110,000 after buying an additional 1,426,465 shares during the last quarter. Westfield Capital Management Co. LP boosted its stake in Lantheus by 25.3% during the first quarter. Westfield Capital Management Co. LP now owns 1,958,018 shares of the medical equipment provider’s stock worth $121,867,000 after buying an additional 394,837 shares during the last quarter. Farallon Capital Management LLC boosted its stake in Lantheus by 595.3% during the first quarter. Farallon Capital Management LLC now owns 1,483,227 shares of the medical equipment provider’s stock worth $92,316,000 after buying an additional 1,269,900 shares during the last quarter. Finally, Reinhart Partners LLC. lifted its stake in shares of Lantheus by 8.4% in the 1st quarter. Reinhart Partners LLC. now owns 1,470,383 shares of the medical equipment provider’s stock valued at $91,517,000 after purchasing an additional 114,110 shares during the last quarter. Institutional investors and hedge funds own 99.06% of the company’s stock.

Analysts Set New Price Targets

LNTH has been the subject of a number of research reports. B. Riley lifted their target price on Lantheus from $95.00 to $99.00 and gave the stock a “buy” rating in a report on Thursday, April 18th. Mizuho lifted their target price on Lantheus from $90.00 to $100.00 and gave the stock a “buy” rating in a report on Friday, May 3rd. JMP Securities reaffirmed a “market outperform” rating and set a $100.00 target price on shares of Lantheus in a report on Friday, February 23rd. StockNews.com cut Lantheus from a “buy” rating to a “hold” rating in a research report on Friday, May 3rd. Finally, Truist Financial lifted their price target on Lantheus from $82.00 to $96.00 and gave the company a “buy” rating in a research report on Friday, May 3rd. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $99.17.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.